Skip to main content
. 2017 Jan 13;18:15. doi: 10.1186/s12882-016-0428-y

Table 5.

Summary of immunosuppressive profile, symptoms and signs, laboratory findings, severity of disease, confirmation of diagnosis and outcome, and comparison with general population

n % Prevalence7a
(n = 81,327) %
p
Immunosuppression
 Azathioprine 166 51.8
 Cyclosporine 166 27.1
 MMF 166 43.4
 Steroid 166 98.8
 Tacrolimus 166 25.9
Symptoms and Signs
 Fever at presentation 162 86.4 98.8 0.006
 Myalgia 159 47.0 92.4 <0.001
 Arthlagia 39 20.2 76.4 <0.001
 New bleeding complications 127 14.9 10.2 0.147
 Headache 133 34.6 95.8 <0.001
 Diarrhea 13 15.3 0.122
 Pleural effusions 115 17.4 2.2 <0.001
 Ascites 23 34.8 1.1 0.003
Laboratory findings
 Thrombocytopenia 127 93.7
 Leucopenia 133 66.9
 LFT abnormalities 39 71.8
 Graft dysfunction 141 58.9
Severity of disease
 DHF / DSS 168 16.0 3.7 <0.001
Confirmation of disease
 IgM 168 87.5
 RT PCR / NS1 168 13.7
Outcome
 Alive with a functioning graft 168 84.5
 Graft failure 168 6.5
 Death 168 8.9 0.062 b <0.001

Abbreviations: LFT liver function tests, RT PCR reverse transcriptase polymerase chain reaction, NS1 non specific antigen 1

aPrevalence of non-transplant population given by Casali CG et al. [14]

bFrequency of DHF given in Casali et al. is 3.7%. The mortality of DHF is 3.21% while that of DF is 0.026%. The combined mortality calculated as 0.062%